11 mayo 2015
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer’s growth.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/zja4jRa-A_o/150511113222.htm
